VA Awards Baylor Genetics Multi-Year Contract for Nationwide Pharmacogenomic and Germline Testing
What the VA’s New Baylor Genetics Contract Means for Clinical Lab Leaders.
For clinical laboratory leaders tracking the growing role of precision medicine in federal healthcare systems, the US Department of Veterans Affairs (VA) has taken another significant step toward broad genomic integration.
Baylor Genetics announced it has been awarded a multi-year national contract to provide pharmacogenomic (PGx) testing and germline genetic testing—including hereditary cancer analysis—to veterans across the VA’s nationwide network.
The company did not disclose the value of the multi-year award. However, federal contract filings indicate that at least one delivery order for PGx testing issued to Baylor Genetics in September was valued at $11.4 million, according to GovTribe.com, which tracks federal contract data.
Targeted Testing to Personalize Care Across the VA
Under the agreement, Baylor Genetics will supply PGx testing designed to help VA clinicians understand how a patient’s genetic makeup may influence their response to medications, particularly those used for mental health conditions. By identifying gene variants that affect drug metabolism and effectiveness, PGx insights can help shorten the time to symptom relief, reduce adverse effects, and support more individualized treatment plans.
The contract also includes hereditary cancer testing to identify genetic risk, inform active surveillance strategies, and guide care decisions for both patients and potentially at-risk family members.
Kengo Takishima, chairman and CEO of Baylor Genetics, noted, “By providing high-quality genetic insights, we aim to empower VA providers with the tools they need to improve treatment outcomes and ensure that those who have served our country receive the best possible care.”
These testing services will be available to all veterans across the VA system.
For lab leaders, the agreement signals continued federal investment in genomic tools that can shape personalized care at scale and highlights the expanding opportunities for laboratories positioned to support large, integrated health networks with advanced testing capabilities.
—Janette Wider
